CHARACTERIZATION OF HEPATIC UPTAKE MECHANISM FOR SN-38, AN ACTIVE METABOLITE OF THE ANTICANCER AGENT IRINOTECAN IN HUMANS

被引：0
|
作者：
Kato, Yukio [1 ]
机构：
[1] Kanazawa Univ, Kanazawa, Ishikawa 9201192, Japan
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [31] Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38
    Iwase, Mariko
    Fujita, Ken-ichi
    Nishimura, Yuki
    Seba, Natsumi
    Masuo, Yusuke
    Ishida, Hiroo
    Kato, Yukio
    Kiuchi, Yuji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (05) : 993 - 998
  • [32] Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38
    Mariko Iwase
    Ken-ichi Fujita
    Yuki Nishimura
    Natsumi Seba
    Yusuke Masuo
    Hiroo Ishida
    Yukio Kato
    Yuji Kiuchi
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 993 - 998
  • [33] P-glycoprotein-dependent pharmacokinetics of irinotecan and its active metabolite, SN-38 in rats: Effect of verapamil
    Garg, Tripta
    Jaggi, Manu
    Khar, Roop K.
    Talegaonkar, Sushama
    ADMET AND DMPK, 2015, 3 (01): : 68 - 76
  • [34] Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients
    Karas, Spinel
    Etheridge, Amy S.
    Tsakalozou, Eleftheria
    Ramirez, Jacqueline
    Cecchin, Erika
    van Schaik, Ron H. N.
    Toffoli, Giuseppe
    Ratain, Mark J.
    Mathijssen, Ron H. J.
    Forrest, Alan
    Bies, Robert R.
    Innocenti, Federico
    AAPS JOURNAL, 2020, 22 (03):
  • [35] Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients
    Spinel Karas
    Amy S. Etheridge
    Eleftheria Tsakalozou
    Jacqueline Ramírez
    Erika Cecchin
    Ron H.N. van Schaik
    Giuseppe Toffoli
    Mark J. Ratain
    Ron H.J. Mathijssen
    Alan Forrest
    Robert R. Bies
    Federico Innocenti
    The AAPS Journal, 22
  • [36] Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure
    Fujita, Ken-ichi
    Masuo, Yusuke
    Okumura, Hidenori
    Watanabe, Yusuke
    Suzuki, Hiromichi
    Sunakawa, Yu
    Shimada, Ken
    Kawara, Kaori
    Akiyama, Yuko
    Kitamura, Masanori
    Kunishima, Munetaka
    Sasaki, Yasutsuna
    Kato, Yukio
    PHARMACEUTICAL RESEARCH, 2016, 33 (02) : 269 - 282
  • [37] Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure
    Ken-ichi Fujita
    Yusuke Masuo
    Hidenori Okumura
    Yusuke Watanabe
    Hiromichi Suzuki
    Yu Sunakawa
    Ken Shimada
    Kaori Kawara
    Yuko Akiyama
    Masanori Kitamura
    Munetaka Kunishima
    Yasutsuna Sasaki
    Yukio Kato
    Pharmaceutical Research, 2016, 33 : 269 - 282
  • [38] High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma
    Schoemaker, NE
    Rosing, H
    Jansen, S
    Schellens, JHM
    Beijnen, JH
    THERAPEUTIC DRUG MONITORING, 2003, 25 (01) : 120 - 124
  • [39] An Accurate Assay for Simultaneous Determination of Irinotecan and Its Active Metabolite SN-38 in Rat Plasma by LC with Fluorescence Detection
    Zhang, Ziqiang
    Yao, Jing
    Wu, Xiaotao
    Zou, Jianjun
    Zhu, Jiabi
    CHROMATOGRAPHIA, 2009, 70 (3-4) : 399 - 405
  • [40] A physiologically based pharmacokinetic modeling approach for predicting the exposure of irinotecan and its active metabolite (SN-38) in cancer patients
    Denic, Kristina Zoran
    Neuhoff, Sibylle
    Reid, Joel
    Kudget, Rachel
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345